BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
George Koutsoudakis, Xavier Forns, Sofía Pérez-del-Pulgar. Biología molecular aplicada del virus de la hepatitis CGastroenterología y Hepatología 2013; 36(4): 280 doi: 10.1016/j.gastrohep.2012.11.005
2
Marion Peyrou, Sophie Clément, Christiane Maier, Lucie Bourgoin, Emilie Branche, Stéphanie Conzelmann, Vincent Kaddai, Michelangelo Foti, Francesco Negro. PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolismJournal of Hepatology 2013; 59(3): 420 doi: 10.1016/j.jhep.2013.04.012
3
G. Grammatikos, H. Farnik, D. Bon, A. Böhlig, T. Bader, T. Berg, S. Zeuzem, E. Herrmann. The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysisJournal of Viral Hepatitis 2014; 21(8): 533 doi: 10.1111/jvh.12274
4
V. Carreño. Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapyAlimentary Pharmacology & Therapeutics 2014; 39(2): 148 doi: 10.1111/apt.12562
5
S. Pollock, N. B. Nichita, A. Bohmer, C. Radulescu, R. A. Dwek, N. Zitzmann. Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cellsProceedings of the National Academy of Sciences 2010; 107(40): 17176 doi: 10.1073/pnas.1009445107
6
Margaret F. Bassendine, David A. Sheridan, Daniel J. Felmlee, Simon H. Bridge, Geoffrey L Toms, R. Dermot G. Neely. HCV and the hepatic lipid pathway as a potential treatment targetJournal of Hepatology 2011; 55(6): 1428 doi: 10.1016/j.jhep.2011.06.004
7
David A. Sheridan, R. Dermot G. Neely, Margaret F. Bassendine. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs)Clinics and Research in Hepatology and Gastroenterology 2013; 37(1): 10 doi: 10.1016/j.clinre.2012.07.002
8
Ching-Sheng Hsu, Wei-Liang Liu, Qisheng Li, Brianna Lowey, Laura Hertz, You-Chen Chao, T. Jake Liang, Ding-Shinn Chen, Jia-Horng Kao. Hepatitis C virus genotypes 1–3 infections regulate lipogenic signaling and suppress cholesterol biosynthesis in hepatocytesJournal of the Formosan Medical Association 2020; 119(9): 1382 doi: 10.1016/j.jfma.2020.03.018
9
Martin Janicko, Sylvia Drazilova, Daniel Pella, Jan Fedacko, Peter Jarcuska. Pleiotropic effects of statins in the diseases of the liverWorld Journal of Gastroenterology 2016; 22(27): 6201-6213 doi: 10.3748/wjg.v22.i27.6201
10
Ben Verpaalen, Johan Neyts, Leen Delang. Are statins a viable option for the treatment of infections with the hepatitis C virus?Antiviral Research 2014; 105: 92 doi: 10.1016/j.antiviral.2014.02.020
11
Paul Targett-Adams, Steeve Boulant, Mark W. Douglas, John McLauchlan. Lipid Metabolism and HCV InfectionViruses 2010; 2(5): 1195 doi: 10.3390/v2051195
12
Cristin Constantin Vere, Costin Teodor Streba, Liliana Streba, Ion Rogoveanu. Statins in the Treatment of Hepatitis CHepatitis Monthly 2012; 12(6): 369 doi: 10.5812/hepatmon.5998
13
Daniel Felmlee, Mohamed Hafirassou, Mathieu Lefevre, Thomas Baumert, Catherine Schuster. Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver DiseaseViruses 2013; 5(5): 1292 doi: 10.3390/v5051292
14
Takasuke Fukuhara, Chikako Ono, Francesc Puig-Basagoiti, Yoshiharu Matsuura. Roles of Lipoproteins and Apolipoproteins in Particle Formation of Hepatitis C VirusTrends in Microbiology 2015; 23(10): 618 doi: 10.1016/j.tim.2015.07.007
15
Scott A. Read, Enoch Tay, Mahsa Shahidi, Jacob George, Mark W. Douglas. Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production Journal of General Virology 2014; 95(9): 1900 doi: 10.1099/vir.0.065300-0
16
David H. Van Thiel, Magdalena George, Bashar M. Attar, Giuliano Ramadori, Niculae Ion-Nedelcu. Plasma Triglyceride Levels May Modulate Hepatitis C Viral ReplicationDigestive Diseases and Sciences 2014; 59(4): 881 doi: 10.1007/s10620-014-3079-5
17
Qianqian Zhu, Na Li, Qunying Han, Pingping Zhang, Cuiling Yang, Xiaoyan Zeng, Yanping Chen, Yi Lv, Xi Liu, Zhengwen Liu. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and meta-analysisAntiviral Research 2013; 98(3): 373 doi: 10.1016/j.antiviral.2013.04.009
18
Naveen Kumar, Shalini Sharma, Ram Kumar, Bhupendra N. Tripathi, Sanjay Barua, Hinh Ly, Barry T. Rouse. Host-Directed Antiviral TherapyClinical Microbiology Reviews 2020; 33(3) doi: 10.1128/CMR.00168-19
19
Andrea Wuestenberg, Janine Kah, Katrin Singethan, Hüseyin Sirma, Amelie Dorothea Keller, Sergio René Perez Rosal, Jörg Schrader, Christine Loscher, Tassilo Volz, Ralf Bartenschlager, Volker Lohmann, Ulrike Protzer, Maura Dandri, Ansgar W. Lohse, Gisa Tiegs, Gabriele Sass, Anna Alisi. Matrix Conditions and KLF2-Dependent Induction of Heme Oxygenase-1 Modulate Inhibition of HCV Replication by FluvastatinPLoS ONE 2014; 9(5): e96533 doi: 10.1371/journal.pone.0096533
20
Steven W. Johnson, Dorothea K. Thompson, Brianne Raccor. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic InterventionsCurrent Infectious Disease Reports 2017; 19(6) doi: 10.1007/s11908-017-0578-5
21
F. Angelico, M. Del Ben. Towards predicting the therapeutic response in patients with hepatitis C: authors’ replyAlimentary Pharmacology & Therapeutics 2009; 31(2): 340 doi: 10.1111/j.1365-2036.2009.04188.x
22
Kyung-Soo Chang, Hyun-Jung Jo. HMG CoA Reductase Inhibitors Inhibit HCV RNA Replication of HCV Genotype 1b but Not 2aJournal of Bacteriology and Virology 2011; 41(2): 99 doi: 10.4167/jbv.2011.41.2.99
23
Koen Vercauteren, Ahmed Atef Mesalam, Geert Leroux-Roels, Philip Meuleman. Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralizationWorld Journal of Gastroenterology 2014; 20(43): 15975-15991 doi: 10.3748/wjg.v20.i43.15975
24
Akira Honda, Yasushi Matsuzaki. Cholesterol and chronic hepatitis C virus infectionHepatology Research 2011; 41(8): 697 doi: 10.1111/j.1872-034X.2011.00838.x
25
David A. Sheridan, Simon H. Bridge, Mary M. E. Crossey, Daniel J. Felmlee, Fiona I. Fenwick, Howard C. Thomas, R. Dermot G. Neely, Simon D. Taylor-Robinson, Margaret F. Bassendine. Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trialLiver International 2014; 34(5): 737 doi: 10.1111/liv.12316
26
Kai Lin, Philippe Gallay. Curing a viral infection by targeting the host: The example of cyclophilin inhibitorsAntiviral Research 2013; 99(1): 68 doi: 10.1016/j.antiviral.2013.03.020
27
Armita M. Gorabi, Nasim Kiaie, Vanessa Bianconi, Tannaz Jamialahmadi, Khalid Al-Rasadi, Thomas P. Johnston, Matteo Pirro, Amirhossein Sahebkar. Antiviral effects of statinsProgress in Lipid Research 2020; 79: 101054 doi: 10.1016/j.plipres.2020.101054
28
L. Milazzo, I. Caramma, C. Mazzali, M. Cesari, M. Olivetti, M. Galli, S. Antinori. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled studyJournal of Antimicrobial Chemotherapy 2010; 65(4): 735 doi: 10.1093/jac/dkq002
29
Valerie A. Villareal, Mary A. Rodgers, Deirdre A. Costello, Priscilla L. Yang. Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C virusesAntiviral Research 2015; 124: 110 doi: 10.1016/j.antiviral.2015.10.013
30
Adeel A. Butt, Peng Yan, Hector Bonilla, Abdul-Badi Abou-Samra, Obaid S. Shaikh, Tracey G. Simon, Raymond T. Chung, Shari S. Rogal. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVESHepatology 2015; 62(2): 365 doi: 10.1002/hep.27835
31
Prashant Pandya, Fadi Rzouq, Olurinde Oni. Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseasesClinics and Research in Hepatology and Gastroenterology 2015; 39(5): 555 doi: 10.1016/j.clinre.2015.02.005